mivacurium and esmolol

We compared the dose-response relationship and the neuromuscular blocking effects of mivacurium during infusions of esmolol in 40 anaesthetised rabbits. Train-of-four stimuli were applied every 10 s to the common peroneal nerve and the force of contraction of the tibialis anterior muscle was measured. Plasma cholinesterase activity decreased by 13% after esmolol infusion. The ED95 of mivacurium increased significantly from 29 (4.8) micrograms.kg-1 with placebo to 61 (9.8) micrograms.kg-1 during esmolol 100 micrograms.kg-1.min-1, 49 (8.2) micrograms.kg-1 during esmolol 300 micrograms.kg-1.min-1 and 54 (7.3) micrograms.kg-1 during esmolol 500 micrograms.kg-1.min-1, respectively (p < 0.001). The duration of neuromuscular block with mivacurium 0.16 mg.kg-1 was prolonged by 30% with esmolol due to diminished plasma cholinesterase activity (p < 0.05). Heart rate and mean arterial blood pressure decreased by 15% with esmolol (p < 0.05). The results of this study show that, in rabbits, esmolol decreased plasma cholinesterase activity, antagonised the neuromuscular blocking potency of mivacurium and prolonged its neuromuscular blocking effect.

Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cholinesterases; Dose-Response Relationship, Drug; Drug Interactions; Heart Rate; Isoquinolines; Mivacurium; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents; Propanolamines; Rabbits

To study the neuromuscular interaction between mivacurium and esmolol, we compared the neuromuscular actions of the ED90 dose of mivacurium both in the absence and presence of esmolol infusion.. Twelve rats were anesthetized with urethane. Train-of-four stimulation was applied every 12 s to the sciatic nerve, and the electromyogram (EMG) response of the anterior tibial muscle was measured.. The ED50 and ED90 of mivacurium in rats were 144 +/- 7.3 micrograms/kg and 197 +/- 7.7 micrograms/kg, respectively. The maximal EMG depression produced by ED50 of mivacurium decreased significantly with esmolol treatment from 88.2 +/- 2.7% to 83.1 +/- 2.6% after esmolol infusion (p < 0.05). The onset time for 75% EMG depression was much shorter for control (44 +/- 6.3 s) than that of esmolol treatment (78.2 +/- 2.4 s; p < 0.05). There was no difference between their duration.. The results of this study demonstrated that esmolol does not potentiate the neuromuscular effect of mivacurium but antagonize the maximal neuromuscular block and decrease its onset time in rats.

Topics: Adrenergic beta-Antagonists; Animals; Drug Interactions; Isoquinolines; Male; Mivacurium; Neuromuscular Junction; Neuromuscular Nondepolarizing Agents; Propanolamines; Rats; Rats, Sprague-Dawley